IPO Profile: Ardelyx Inc

Investors, including Amgen, CMEA and NEA, invested $56 million in the drug developer that focuses on the gastrointestinal tract

ByLarry Oberfeld

1 July 2014•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.